Unlocking the Diagnostic Potential of Tear Fluid
A proprietary platform for standardized tear biopsy, biomarker preservation, and AI-enabled molecular analysis.
"The eye is the window of the soul and the chief organ whereby the understanding may most fully and abundantly appreciate the infinite works of nature."
— Leonardo da Vinci
Tear fluid is an underexplored source of molecular information with significant potential for precision diagnostics. BioDrop is developing technologies that enable standardized collection and preservation of tear-derived biomarkers for downstream molecular analysis.
Why Tears?
Rich source of molecular biomarkers
Non-invasive and patient-friendly collection
Suitable for repeated longitudinal monitoring
Potential applications across neurology, oncology, ophthalmology, and systemic disease
The Future of Liquid Biopsy Is in the Eye
Our Platform
Why It Matters
Patent-pending diagnostic technologies
International Scientific Advisory Board
Growing network of academic and clinical collaborations
Founded by a physician-scientist with over two decades of biomedical research experience
European deep-tech company developing next-generation molecular diagnostics
BioDrop combines proprietary biomarker collection, preservation chemistry, molecular analysis, and artificial intelligence into a unified diagnostic platform.
Our approach is designed to support:
Standardized biomarker collection
Preservation of molecular integrity
Multi-omics research applications
AI-assisted interpretation of complex biological data
Advancing Precision Diagnostics
Early detection remains one of the greatest challenges in modern medicine. Many diseases are diagnosed only after symptoms appear, when treatment options may already be limited.
BioDrop is developing technologies that enable standardized, non-invasive molecular sampling, helping unlock biological information that could support earlier detection, more precise monitoring, and future advances in personalized medicine.
Current diagnostic approaches often involve:
Invasive sampling procedures
Hospital-based testing
Delayed detection after clinical symptoms emerge
From sample collection to computational interpretation, BioDrop is building an integrated platform for the next generation of precision diagnostics.
BioDrop Solutions is developing a platform for non-invasive molecular diagnostics based on tear biopsy. By integrating standardized sample collection, biomarker preservation, and computational analysis, we aim to expand access to precision diagnostics while enabling new opportunities for multi-omics research and artificial intelligence in medicine.
What Makes Us Different:
Transforming Tears into Diagnostic Innovations
BioDrop Solutions is developing an integrated platform for non-invasive molecular diagnostics based on tear biopsy. By combining proprietary biomaterial engineering, biomarker preservation, molecular analysis, and computational interpretation, we aim to expand the clinical potential of tear-derived biomarkers.
We are presenting a fresh and innovative approach:
Standardized tear biopsy using proprietary biomaterials
Preservation of molecular integrity during collection and transport
Compatibility with multi-omics and AI-enabled analysis
Designed for scalable research and future clinical applications
Initial Clinical Focus
BioDrop's initial development program is focused on glioma, where improved access to non-invasive molecular biomarkers could address a significant unmet clinical need. The underlying platform is designed to support future applications across neurodegenerative, ophthalmological, oncological, and systemic diseases as scientific validation expands.
Revolutionary Tear Diagnostics
Transforming tears into diagnostic tools for early disease detection and monitoring with innovative technology.
Tear Collection Technology
Imagine a world where diagnosing brain tumors and neurodegenerative diseases is as simple as shedding a tear. Our project aims to achieve this with a revolutionary tear collection method.
We are creating a biocompatible, single-use lens that collects and preserves genetic samples from tears while ensuring patient comfort. The material we use regulates pH levels, which is vital for maintaining the integrity of microRNAs. This innovative approach provides a quick, non-invasive, and painless alternative to traditional diagnostic blood or CSF tests.
Liquid biopsy screening is a significant advancement in cancer diagnostics, enabling early detection and continuous monitoring by analyzing circulating DNA, exosomes, and cell-free RNA. This approach provides real-time insights and overcomes traditional diagnostic limitations.
Additionally, tear collection offers a non-invasive and safe diagnostic method ensuring a comfortable experience for patients.
Our goal is to deliver unique services at low costs, creating an untapped market space that attracts a wider audience and redefines healthcare standards.
Tears provide a unique advantage for assessing biomarkers related to brain pathologies due to their connection with the lacrimal and meibomian glands and the brain.
They contain diverse molecular components, including significant amounts of microRNAs, which regulate around 60% of human protein-coding genes. Abnormal expression of these microRNAs is closely linked to cancer development, underscoring their diagnostic potential in health and disease.
Tears
Liquid biopsy
Brain cancer diagnosis
An innovative tear microRNA analysis for early non-invasive glioma diagnosis
Every year, more than 250,000 new cases of primary malignant brain tumors are diagnosed globally, with gliomas representing approximately 80% of these alarming figures. A myriad of factors contributes to an individual's risk of developing gliomas, including age and race, which are unfortunately beyond our control. Nevertheless, there is a glimmer of hope in the realm of early detection and intervention for low-grade gliomas. When these early-stage tumors are identified swiftly, they can be managed with greater efficacy, potentially slowing their progression and diminishing the risk of their advancement to more aggressive, high-grade gliomas. By emphasizing early intervention, we can significantly improve outcomes and enhance the quality of life for patients at risk.
Traditionally, diagnosing brain tumors has involved invasive procedures, such as tissue biopsies, which can be a source of unnecessary anxiety and present risks for patients who may not even have cancer. In light of this, we propose a more compassionate and innovative approach: a non-invasive alternative that analyzes microRNA present in tears to detect gliomas in their nascent stages.
Our hypothesis suggests that a unique microRNA signature found in tear samples may serve as an indicator of glioma presence. This groundbreaking method has the potential to pave the way for the development of rapid, cost-effective, and non-invasive screening tests. A diagnostic technique centered around tear analysis could revolutionize the way healthcare providers detect and monitor brain tumors, with the prospect of early detection saving countless lives.
The underlying science of tear-based liquid biopsy holds tremendous promise, and we are committed to developing a cutting-edge sample collection method paired with advanced microRNA analysis technology. My strategy for clinical implementation appears highly promising. This straightforward yet powerful diagnostic tool could significantly enhance the efficacy of glioma detection worldwide, transforming the landscape of brain tumor diagnostics for clinicians and patients alike.
★★★★★
Contact Us for Innovative Solutions
Reach out to learn more about our groundbreaking tear-collecting technology.
